Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft synthesis: Counter-ion content and its effect on… — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-106/3
Series
Public comment period
Version
1.0
Published
01 Sep 2024
Last reviewed
01 Sep 2024
Next review
01 Sep 2025
Identifier
10.71829/cei.cp.106
Certainty
Not rated
Cycle
2024 Q3
Window
09 Jul 2024 – 06 Aug 2024
Status
Closed
Submissions
16

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-COUNTERION-C/001Ms Rhiannon Okoye-VandergraafThe document is unreadable without specialist trainingAccepted in part
DRAFT-COUNTERION-C/002Dr Matthias Wintringham industryThe document should not describe uses outside the approved indicationNot accepted
DRAFT-COUNTERION-C/003Stellan Cholmondeley-AdeReferences should carry a persistent identifier for every cited sourceAccepted in part
DRAFT-COUNTERION-C/004Dr Ivo QuintanilhaRisk-of-bias judgements are reported as an overall rating without the domainsAccepted
DRAFT-COUNTERION-C/005Dr Oswin YorkstoneWhether the analyst knew the source of each sample is not reportedNoted, no amendment
DRAFT-COUNTERION-C/006Thaddeus Isaksen-BalogunStudies using different outcome definitions are pooled into one estimateAccepted
DRAFT-COUNTERION-C/007Dr Eamon ImmelmannThe chain of custody between purchase and analysis is not describedNoted, no amendment
DRAFT-COUNTERION-C/008Professor Bartolomeu Nkosi-LindegaardContributing surveys anonymise their sources to different degreesNoted, no amendment
DRAFT-COUNTERION-C/009Dr Vasilisa ImmelmannRegulatory assessment documents were not searchedAccepted in part
DRAFT-COUNTERION-C/010Ivo MountstephenA superseded version should remain reachable from the version that replaced itNoted, no amendment
DRAFT-COUNTERION-C/011Dr Yaa KettlewellA funnel plot is presented for a set too small to interpret itAccepted
DRAFT-COUNTERION-C/012Quentin Whitmarsh-ObiThe search strategy as published cannot be re-runAccepted
DRAFT-COUNTERION-C/013Dr Ndidi Ravensworth-IlungaThe sampling frame of each contributing survey is not reportedAccepted
DRAFT-COUNTERION-C/014Dr Jozef Brandvold-AchterbergThe conclusion is stated more strongly than the certainty rating supportsAccepted
DRAFT-COUNTERION-C/015Dr Melisande Kirkpatrick-OlaTwo included studies do not meet the registered eligibility criteriaAccepted in part
DRAFT-COUNTERION-C/016Dr Quentin ZimmerthalResults obtained by different methods are pooled without recording the methodAccepted
16 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted7The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part4Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment4The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted1The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. The document is unreadable without specialist training — arising from DRAFT-COUNTERION-C/001. Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.
  2. References should carry a persistent identifier for every cited source — arising from DRAFT-COUNTERION-C/003. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
  3. Risk-of-bias judgements are reported as an overall rating without the domains — arising from DRAFT-COUNTERION-C/004. Risk of bias is now reported at domain level for every included study, with the text on which each judgement was based quoted and referenced, and the overall judgement derived from the domains rather than asserted alongside them.
  4. Studies using different outcome definitions are pooled into one estimate — arising from DRAFT-COUNTERION-C/006. Studies are now pooled only within an outcome definition, each definition is reported with its own estimate and certainty rating, and the summary of findings states which definition each row concerns.
  5. Regulatory assessment documents were not searched — arising from DRAFT-COUNTERION-C/009. Published regulatory assessment documents are now searched as a named source, are reported as a distinct evidence class in the included-studies table, and contribute to the assessment while being excluded from pooled estimates where risk of bias could not be…
  6. A funnel plot is presented for a set too small to interpret it — arising from DRAFT-COUNTERION-C/011. The funnel plot is removed for every outcome contributed by fewer than ten studies, and replaced by a statement that small-study effects could not be assessed at that number, together with the count of registered trials identified without posted results.
  7. The search strategy as published cannot be re-run — arising from DRAFT-COUNTERION-C/012. The full line-by-line strategy for each database is now published with the interface, the run date and the yield at each line, and the total retrieved is reconciled against the screening flow.
  8. The sampling frame of each contributing survey is not reported — arising from DRAFT-COUNTERION-C/013. Every contributing survey now carries a sampling row stating the frame, the number of sources approached and the number supplying, and the synthesis reports separately for surveys whose frames are not comparable.
  9. The conclusion is stated more strongly than the certainty rating supports — arising from DRAFT-COUNTERION-C/014. Conclusion wording is now drawn from a fixed set of formulations tied to the certainty rating, so that a low certainty rating produces a statement that the evidence may suggest an effect and that the estimate is likely to change with further research.
  10. Two included studies do not meet the registered eligibility criteria — arising from DRAFT-COUNTERION-C/015. One study has been removed from the included set and the estimate recomputed, the exclusion reason for the third study has been corrected in the excluded-studies table, and the screening decisions are now recorded against the protocol version in force at the…
  11. Results obtained by different methods are pooled without recording the method — arising from DRAFT-COUNTERION-C/016. Every contributing result now carries its determination, pooling occurs only within a determination, and where a survey did not report the method the result is listed as method not stated and excluded from the pooled estimates.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.